If a patient with suspected or confirmed MASH cannot tolerate the GLP-1 receptor agonist dose and can only maintain a lower obesity-approved dose, do you continue that lower dose as part of a liver-directed strategy or pivot earlier to a thyroid hormone receptor-beta agonist (or combination therapy) to avoid undertreating fibrosis risk?